1832 Asset Management
KRYS icon

1832 Asset Management’s Krystal Biotech KRYS Stock Holding History

1832 Asset Management’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$11M Buy
42,600
+25,000
+142% +$6.65M 0.01% 360
2025
Q4 		$4.34M Buy
+17,600
New +$3.7M ﹤0.01% 448
2025
Q2 		– Sell
-136,000
Closed -$24.5M – 718
2025
Q1 		$24.5M Buy
+136,000
New +$22.9M 0.02% 270

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

1832 Asset Management's KRYS Position: Q1 2026 in Review

1832 Asset Management increased its Krystal Biotech (KRYS) stake by 142% in Q1 2026, buying an estimated $6.65M and bringing the position to 42,600 shares worth $11M. The position accounts for 0.01% of the portfolio, ranked #360.

1832 Asset Management first reported a position in KRYS in Q1 2025 and has held it in 3 quarters since. The position peaked at $24.5M in Q1 2025. 367 funds tracked by Wall St. Rank hold KRYS as of Q1 2026.

  • 1832 Asset Management held 42,600 shares of Krystal Biotech worth $11M as of Q1 2026.
  • 1832 Asset Management bought 25,000 Krystal Biotech shares in Q1 2026, an estimated $6.65M.
  • Krystal Biotech made up 0.01% of 1832 Asset Management's portfolio in Q1 2026, its #360 holding.
  • 1832 Asset Management first reported a position in Krystal Biotech in Q1 2025 and has held it in 3 quarters since.
  • 1832 Asset Management's Krystal Biotech position peaked at $24.5M in Q1 2025.
  • 367 funds tracked by Wall St. Rank held Krystal Biotech as of Q1 2026.

Based on 1832 Asset Management's 13F filing for Q1 2026, filed 14 May 2026.